[PROVISIONAL] Resistance mutations of NS3 and NS5b in treatment-naïve patients infected with Hepatitis C virus in Santa Catarina and Rio Grande do Sul States, Brazil.
Hepatitis C virus (HCV) infection is a worldwide health problem. Nowadays, direct-acting antiviral agents (DAAs) are the main treatment; however, the high level of variability of HCV lead to development of resistance-associated variants (RAVs). Thus, look into the RAVs among infected patients is an important tool for monitoring the efficacy of the therapy. The aim of our study was to investigate the presence of naturally occurring resistance mutations in HCV NS3 and NS5 regions in treatment-naïve patients. Ninety-six anti-HCV positive serum samples from blood donors at Center of Hematology and Hemotherapy of Santa-Catarina State (HEMOSC) were collected retrospectively in 2013, and evaluated in this study. HCV subtypes 1a (37.9%), 1b (25.3%) and 3a (36.8%) were found. The frequency of patients with RAVs in our study was 6.9%. The HCV NS5b sequencing reveled 1 sample with L320F mutation and 4 samples with the polymorphism C316N/R. The analysis of the NS3 region revealed mutations D168A/G/T (3.45%), S122G (1.15%) and V55A (2.3%). All samples from genotype 3a (36.8%) presented the non-synonymous mutation V170 I/V. In conclusion, we have shown that mutation in NS3 and NS5b genes are present in Brazilian isolates from therapy-naïve patients.